[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60207652D1 - Durch Säuregruppen disubstitierte Heteroaryl-Derivate und ihre Verwendung als Matrix Metalloproteinas Inhibitoren - Google Patents

Durch Säuregruppen disubstitierte Heteroaryl-Derivate und ihre Verwendung als Matrix Metalloproteinas Inhibitoren

Info

Publication number
DE60207652D1
DE60207652D1 DE60207652T DE60207652T DE60207652D1 DE 60207652 D1 DE60207652 D1 DE 60207652D1 DE 60207652 T DE60207652 T DE 60207652T DE 60207652 T DE60207652 T DE 60207652T DE 60207652 D1 DE60207652 D1 DE 60207652D1
Authority
DE
Germany
Prior art keywords
matrix metalloproteinase
heteroaryl derivatives
acid groups
metalloproteinase inhibitors
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60207652T
Other languages
English (en)
Other versions
DE60207652T2 (de
Inventor
R Sorenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE60207652D1 publication Critical patent/DE60207652D1/de
Application granted granted Critical
Publication of DE60207652T2 publication Critical patent/DE60207652T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE60207652T 2001-09-10 2002-08-27 Durch Säuregruppen disubstitierte Heteroaryl-Derivate und ihre Verwendung als Matrix Metalloproteinas Inhibitoren Expired - Lifetime DE60207652T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31848801P 2001-09-10 2001-09-10
US318488P 2001-09-10

Publications (2)

Publication Number Publication Date
DE60207652D1 true DE60207652D1 (de) 2006-01-05
DE60207652T2 DE60207652T2 (de) 2006-07-13

Family

ID=23238384

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60207652T Expired - Lifetime DE60207652T2 (de) 2001-09-10 2002-08-27 Durch Säuregruppen disubstitierte Heteroaryl-Derivate und ihre Verwendung als Matrix Metalloproteinas Inhibitoren

Country Status (9)

Country Link
US (1) US6924276B2 (de)
EP (1) EP1291345B1 (de)
JP (1) JP3916064B2 (de)
AT (1) ATE311380T1 (de)
BR (1) BR0203644A (de)
CA (1) CA2401358A1 (de)
DE (1) DE60207652T2 (de)
ES (1) ES2250591T3 (de)
MX (1) MXPA02008236A (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
ATE472535T1 (de) * 2001-02-14 2010-07-15 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
CA2433778A1 (en) * 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
US6881741B2 (en) * 2001-06-11 2005-04-19 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
EP1536786A1 (de) * 2002-07-17 2005-06-08 Warner-Lambert Company Llc Kombination eines allosterischen hemmers von matrix-metalloproteinase-13 mit celecoxib oder valdecoxib
EP1531904A1 (de) * 2002-07-17 2005-05-25 Warner-Lambert Company LLC Pharmazeutische zusammensetzung enthaltend einen allosterischen matrix-metalloproteinase-13-inhibitor sowie einen cyclooxygenase-2-inhibitor der nicht celecoxib oder valdecoxib ist
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
MXPA05001786A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014354A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
AU2003250469A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Isoquinoline derivatives as matrix metalloproteinase inhibitors
JP2006501215A (ja) * 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
WO2004014868A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
WO2004014909A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004014923A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
EP1394159A1 (de) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Neue Thiophen-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
PT1569929E (pt) 2002-12-10 2010-06-18 Virochem Pharma Inc Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
EP1778686B9 (de) 2004-08-12 2009-07-08 Pfizer Limited Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
CN101007798B (zh) * 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
CN101007804B (zh) * 2006-01-25 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 1,3-苯并间二氧杂环戊烯-2,2-二羧酸衍生物、其制备方法和医疗用途
EA201101492A1 (ru) * 2006-11-15 2012-09-28 Вирокем Фарма Инк. Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
CN103012190B (zh) * 2012-12-05 2015-03-18 江苏拜克新材料有限公司 一种s-2-氨基丁酰胺盐酸盐的合成方法
KR102504844B1 (ko) * 2019-02-01 2023-03-02 울산과학기술원 엔도트로핀 절단 효소의 저해제를 포함하는 엔도트로핀 활성 저해용 조성물 및 이의 용도
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US151558A (en) * 1874-06-02 Improvement in the modes of machine-sewing
US161000A (en) * 1875-03-23 Improvement in millstone-bushes
US156061A (en) * 1874-10-20 Improvement in boot and shoe nails
US130278A (en) * 1872-08-06 Improvement in pipe-tongs
US156069A (en) * 1874-10-20 Improvement in lithographic printing-presses
US4172A (en) * 1845-09-02 Coal-breaker
US151555A (en) * 1874-06-02 Improvement in street-railway switches
US193377A (en) * 1877-07-24 Improvement in bee-hives
NL269564A (de) 1960-09-26
CH437347A (de) 1961-07-20 1967-06-15 Ciba Geigy Verfahren zur Herstellung eines Dichlor-tetrahydrothiophen-2,5-dicarbonsäuredichlorides
CH406631A (de) 1964-01-17 1966-01-31 Ciba Geigy Verwendung von neuen 2,5-Dibenzoxazolyl-thiophen-Verbindungen als optische Aufhellmittel für nicht-textile Materialien
CH475301A (de) 1964-10-27 1969-07-15 Ciba Geigy Verfahren zur Herstellung von mit Oxazolverbindungen optisch aufgehellten Formkörpern
US4010174A (en) 1971-07-28 1977-03-01 Bayer Aktiengesellschaft Thiazolinone-(2)-carboxylic acid esters and process therefor
DE2253027A1 (de) 1972-10-28 1974-05-09 Bayer Ag Fungizide mittel
US3928413A (en) 1973-04-13 1975-12-23 Zoecon Corp Cyclopropanemethyl esters
US3925460A (en) 1973-11-08 1975-12-09 Zoecon Corp Esters of cyclopropane substituted carboxylic acids
US4093622A (en) 1975-05-19 1978-06-06 Zoecon Corporation Pyridine esters of cyclopropane-carboxylic acid
MX9203460A (es) 1988-09-12 1992-09-01 Upjohn Co Nuevos analogos cc-1065 que tienen dos subunidades cpi.
DE69032378T2 (de) 1989-03-13 1998-10-01 Sumitomo Seika Chemicals Ein Verfahren zur Herstellung von Dibenzoxazolylthiophenen
US5425289A (en) 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3931432A1 (de) 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
DE4020570A1 (de) 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
JPH05303181A (ja) * 1992-04-27 1993-11-16 Konica Corp ハロゲン化銀カラー写真感光材料
EP0667773A4 (de) * 1992-10-14 1996-09-25 Merck & Co Inc Fibrinogen-rezeptor-antagonisten.
CN1122696C (zh) 1994-09-30 2003-10-01 赫彻斯特股份公司 聚(对亚苯基亚乙烯基)衍生物及其作为场致发光材料的用途
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US6090947A (en) 1996-02-26 2000-07-18 California Institute Of Technology Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
BR9714385A (pt) * 1996-12-09 2000-05-16 Warner Lambert Co Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
JPH10269008A (ja) 1997-03-27 1998-10-09 Pentel Kk 平行抵抗膜方式座標検出装置
JP4344960B2 (ja) 1997-05-23 2009-10-14 バイエル、コーポレイション アリール尿素によるｐ３８キナーゼ活性の阻害
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
EP1091952B1 (de) 1998-06-29 2003-10-29 Biochem Pharma Inc Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
AU1179000A (en) 1998-11-19 2000-06-13 Shionogi & Co., Ltd. Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect
JP3828364B2 (ja) 1999-03-10 2006-10-04 塩野義製薬株式会社 ［２．２．１］および［３．１．１］ビシクロ骨格を有するｐｇｄ２／ｔｘａ２両受容体拮抗性医薬組成物
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
HN2000000137A (es) 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
AU2001232113A1 (en) 2000-02-21 2001-09-03 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (de) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituierte Sulfonylhydroxamsäuren mit MMP inhibierender Wirkung
CN1501937A (zh) 2000-10-26 2004-06-02 �Ʒ� 螺-嘧啶-2,4,6-三酮金属蛋白酶抑制剂
PL362919A1 (en) 2000-10-26 2004-11-02 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
US7030204B2 (en) * 2001-02-09 2006-04-18 Lonza Ag Novolak cyanate-based prepolymer compositions
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
DOP2002000334A (es) 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
ATE472535T1 (de) 2001-02-14 2010-07-15 Warner Lambert Co Pyrimidinmatrixmetalloproteinaseinhibitoren
CA2433778A1 (en) 2001-02-14 2002-08-22 William Glen Harter Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
MXPA03005870A (es) 2001-02-14 2005-02-14 Warner Lambert Co Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
UY27485A1 (es) 2001-10-12 2003-05-30 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado
US6933298B2 (en) 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
DE10160357A1 (de) 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen

Also Published As

Publication number Publication date
BR0203644A (pt) 2003-06-03
EP1291345A1 (de) 2003-03-12
CA2401358A1 (en) 2003-03-10
JP3916064B2 (ja) 2007-05-16
ES2250591T3 (es) 2006-04-16
US20030087924A1 (en) 2003-05-08
EP1291345B1 (de) 2005-11-30
DE60207652T2 (de) 2006-07-13
ATE311380T1 (de) 2005-12-15
JP2003128672A (ja) 2003-05-08
MXPA02008236A (es) 2005-07-13
US6924276B2 (en) 2005-08-02

Similar Documents

Publication Publication Date Title
DE60207652D1 (de) Durch Säuregruppen disubstitierte Heteroaryl-Derivate und ihre Verwendung als Matrix Metalloproteinas Inhibitoren
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
ATE344033T1 (de) Vinylphenyl-derivate als glk-aktivatoren
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
SE0102300D0 (sv) Compounds
ATE450534T1 (de) Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
ATE368656T1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
DE60330015D1 (de) Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten
ATE377010T1 (de) Caspase-inhibitoren und ihre verwendungen
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
ATE293617T1 (de) Oxybenzamidderivate als faktor-xa-inhibitoren
SE0104140D0 (sv) Novel Compounds
CY1106969T1 (el) Αναστολεις dpp-iv
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
ATE275554T1 (de) Serinprotease-inhibitoren
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
EA200401114A2 (ru) Замещённые гидроксиэтиламины
ATE527261T1 (de) 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten
TWI256890B (en) Hetero biaryl derivatives as matrix metalloproteinase inhibitors
TR200201168T2 (tr) CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri.
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
NO20060718L (no) Substituerte tiofoner og deres anvendelse
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition